EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Spatial single-cell proteotyping reveals immunotherapy-resistant features within the complex tumor microenvironment of metastatic NSCLC

Kohsuke Isomoto, Koji Haratani, Takahiro Tsujikawa, Shuta Tomida, Yusuke Makutani, Masayuki Takeda, Kimio Yonesaka, Kaoru Tanaka, Tsutomu Iwasa, Kazuko Sakai, Kazuto Nishio, Akihiko Ito und 2 weitere

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci195021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Kohsuke Isomoto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Tumor Microenvironment, Lung Neoplasms, Single-Cell Analysis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Osaka Cancer Society, YOKOYAMA Foundation for Clinical Pharmacology, SGH Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Immune checkpoint inhibitors (ICIs) targeting the programmed cell death 1 axis have revolutionized metastatic non–small cell lung cancer (mNSCLC) treatment. However, disease progression remains a concern, and the role of the complex tumor microenvironment (TME) in treatment failure is not fully understood. METHODS In this biomarker study involving 103 patients with mNSCLC, including 81 patients who received ICI treatment, we evaluated the association between heterogeneous immune cell subsets and ICI efficacy through single-cell spatial profiling of pretreatment tumor tissue, using a 29-marker multiplex IHC platform built for in-depth dissection of the TME. RESULTS Among various types of intratumoral lymphocytes, including Th1, Treg, and NK cells, only CD8 + T cells (tumor-infiltrating lymphocytes [TILs]) were associated with ICI efficacy. Computational tissue segmentation underscored the importance of direct physical interactions between CD8 + TILs and cancer cells for ICI efficacy. TIL phenotyping identified CD39/CD103/Ki-67 positivity as a hallmark of exhausted yet functional tumor-reactive CD8 + TILs. Immunosuppressive tumor-associated macrophages (TAMs) and cancer-associated fibroblasts were independent unfavorable adversaries. High CD73 expression on cancer cells was suggested to confer tolerance to ICI in EGFR/ALK -oncogene + NSCLC, potentially through M2-TAM accumulation and aberrant angiogenesis. CONCLUSION Our study delineates the clinical relevance of heterogeneous immune cell subsets in ICI-treated mNSCLC, aiding the development of targeted therapeutic strategies. FUNDING Osaka Cancer Society, KANAE Foundation for the Promotion of Medical Science, SGH Foundation, and YOKOYAMA Foundation for Clinical Pharmacology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungTumor MicroenvironmentLung NeoplasmsSingle-Cell AnalysisImmunotherapyImmune Checkpoint InhibitorsDrug Resistance, NeoplasmHumansFemaleLymphocytes, Tumor-InfiltratingMaleNeoplasm MetastasisCD8-Positive T-LymphocytesMiddle AgedAged

Stichwörter der Autor:innen

BiomarkersCancer immunotherapyClinical ResearchImmunologyLung cancerOncology

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
  • Department of Surgery.
  • Department of Genome Biology, and.

Förderung

  • the Osaka Cancer Society
  • YOKOYAMA Foundation for Clinical Pharmacology
  • SGH Foundation
  • Kanae Foundation for the Promotion of Medical Science

Zitieren

APA

Isomoto, K., Haratani, K., Tsujikawa, T., Tomida, S., Makutani, Y., Takeda, M., Yonesaka, K., Tanaka, K., Iwasa, T., Sakai, K., Nishio, K., Ito, A., Nakagawa, K., & Hayashi, H. (2026). Spatial single-cell proteotyping reveals immunotherapy-resistant features within the complex tumor microenvironment of metastatic NSCLC. Journal of Clinical Investigation. https://doi.org/10.1172/jci195021

Vancouver

Isomoto K, Haratani K, Tsujikawa T, Tomida S, Makutani Y, Takeda M, et al. Spatial single-cell proteotyping reveals immunotherapy-resistant features within the complex tumor microenvironment of metastatic NSCLC. Journal of Clinical Investigation. 2026. doi:10.1172/jci195021

BibTeX
@article{Isomoto2026,
  author = {Isomoto, Kohsuke and Haratani, Koji and Tsujikawa, Takahiro and Tomida, Shuta and Makutani, Yusuke and Takeda, Masayuki and Yonesaka, Kimio and Tanaka, Kaoru and Iwasa, Tsutomu and Sakai, Kazuko and Nishio, Kazuto and Ito, Akihiko and Nakagawa, Kazuhiko and Hayashi, Hidetoshi},
  title = {Spatial single-cell proteotyping reveals immunotherapy-resistant features within the complex tumor microenvironment of metastatic NSCLC},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci195021}
}
Kostenlos starten →